P854 Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitisEmi Khoo, Jakob Begun, Anna Amiss et al.|Journal of Crohn s and Colitis|2024Cited by 6
Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated AnemiaKavita Bisht, Jean-Pierre Lévesque, Yoon‐Kyo An et al.|Blood|2024Cited by 1
Australian Real‐World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Results of the <scp>AURORA</scp> Study, Including the <scp>ANZIBD</scp> ConsortiumYoon‐Kyo An, Jakob Begun, Anna Amiss et al.|JGH Open|2025Cited by 1
P663 Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn’s disease patients: results from the AURORA Study including ANZIBDC CohortYoon‐Kyo An, Jakob Begun, Niamh Lindsay et al.|Journal of Crohn s and Colitis|2023Cited by 0
903 TOFACITINIB DEMONSTRATES PRELIMINARY EFFICACY IN INDUCTION OF REMISSION IN CHRONIC POUCHITISEmi Khoo, Jakob Begun, Anna Amiss et al.|Gastroenterology|2024Cited by 0